Moreover, mechanistic studies using several AML and chronic myeloid leukemia (CML) cell lines showed the induction of cell cycle arrest and inhibition of ERK1/2 and AKT/mTOR pathways [18] (Table 1). The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.